LinkedIn logo

Seth J. Baum MD, MASPC, FACC, FAHA, FNLA

Chief Medical Officer, Cardiovascular/Metabolic Lead

Dr. Seth J. Baum, Chief Medical Officer of Flourish Research, graduated from Columbia College and Columbia Medical School, with advanced fellowship training in cardiology, interventional cardiology, and electrophysiology. He currently serves as a Clinical Affiliate Professor of Cardiology at the Charles E. Schmidt College of Medicine, Florida Atlantic University.

He is a Master of the American Society for Preventive Cardiology and holds fellowships with numerous organizations, including the American College of Cardiology, the American Heart Association, the American College of Preventive Medicine, and the National Lipid Association.

With two books and over 150 peer-reviewed papers and abstracts, Dr. Baum has been published in leading journals such as Nature, The Journal of the American College of Cardiology, Circulation, The New England Journal of Medicine, and The Lancet.

Since 2000, his primary focus has been on Preventive Cardiology and Clinical Lipidology. In 2005, he was among the first group to become Board Certified by the American Board of Clinical Lipidology. Dr. Baum has held leadership roles at the American Society for Preventive Cardiology (ASPC) since 2010, eventually becoming its President in 2016. He has also been an active member of the Family Heart Foundation since 2015, serving on its Board of Directors and Scientific Advisory Board. In 2024, he was elected Chairman of the Family Heart Foundation’s Board of Directors.

Dr. Baum is deeply passionate about advancing research in cardiovascular and metabolic health, with a focus on improving patient outcomes and fostering innovation in the field. In recognition of his lifelong dedication to Preventive Medicine, he was awarded Cleveland Heart Lab’s “Heart Award” in 2013. In 2019, Mended Hearts honored him with the biennial Dwight Emary Harken Award.

In 2016, Dr. Baum founded Excel Medical Clinical Trials (EMCT), initially focusing on lipid and lipoprotein disorders. In 2021, EMCT was selected as one of two platform sites that founded Flourish Research. Since then, Flourish’s therapeutic focus has expanded to three areas, Cardiovascular/Metabolic/Renal, Neuroscience, and Infectious Disease. Since 2022, Dr. Baum has served as Flourish’s Chief Medical Officer, helping grow the organization into a leading site network that currently spans the United States.

“It has been a privilege to help thousands of patients during my nearly 40-year career in Medicine. Working in clinical research, however, has enabled me to dramatically expand my reach. Participating in clinical trials, I have been fortunate to help bring life-saving medications to literally millions of people. Flourish Research fosters excellence in all aspects of the conduct of clinical trials and I am proud to be a part of the company.”

Contact us about your next trial at bd@flourishresearch.com.

Flourish Research News

Stay current with the latest clinical trial news and learn how Flourish Research is supporting the advancement of life-changing therapeutics.